关键词：肽；化学氨基酸；有机化合物；生物活性物质
摘 要：Peptides are organic compounds that are composed of amino acids linked together chemically by peptide bonds. They are among the most potent biologically active substances found in nature, and are used to control, trigger, and maintain physiological processes in living beings. However, the use of peptides as therapeutic agents has always been difficult because of their inherent instability and incapability of passing through cellular membranes. Peptides also entail the requirement of specific technology to tackle the extensive and challenging steps in their synthesis. Currently, there are more than 80 peptides marketed by various companies. The companies continue to explore the probability of designing and engineering peptides that overcome their natural confines, so as to be used as therapeutic agents.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Route of

Administration

07.1 Parenteral

07.2 Oral

07.3 Pulmonary

07.4 Mucosal

08. Market Segmentation by Drug Class

08.1 Somatostatins

08.2 Vasopressin

08.3 Calcitonins

08.4 LHRH

08.5 Glucagon and Analogs

08.6 Insulins

08.7 Others

09. Market Segmentation by Technology

09.1 Liquid-phase Peptide Synthesis

09.2 Solid-phase Peptide Synthesis

09.3 Hybrid Peptide Synthesis0

10. Geographical Segmentation

10.1 Peptide Therapeutics Market in Americas

10.1.1 Market Size and Forecast

10.2 Peptide Therapeutics Market in EMEA Region

10.2.1 Market Size and Forecast

10.3 Peptide Therapeutics Market in APAC Region

10.3.1 Market Size and Forecast

11. Peptide Synthesis

12. Optimization of Peptides

12.1 Ligation

12.2 Cyclization

12.3 Heterodimerization

12.4 Cytoconjugation

13. Stabilization of Peptides

13.1 Stapled Peptides

13.2 Disulfide-rich Peptides

13.3 Other Constrained Peptides

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.1.2 Mergers and Acquisitions

21.2 Market Share Analysis

21.3 Other and Future Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

23.1 AstraZeneca

23.1.1 Key Facts

23.1.2 Business Description

23.1.3 Business Segmentation

23.1.4 Business Strategy

23.1.5 Business Segmentation by Revenue

23.1.6 Revenue Comparison 2011-2013

23.1.7 Geographical Segmentation by Revenue

23.1.8 Key Developments

23.1.9 SWOT Analysis

23.2 Eli Lilly

23.2.1 Key Facts

23.2.2 Business Overview

23.2.3 Business Segmentation by Revenue 2013

23.2.4 Business Segmentation by Revenue 2012 and 2013

23.2.5 Geographical Segmentation by Revenue

23.2.6 Business Strategy

23.2.7 Key Information

23.2.8 SWOT Analysis

23.3 Novo Nordisk

23.3.1 Key Facts

23.3.2 Business Overview

23.3.3 Business Segmentation by Revenue 2013

23.3.4 Business Segmentation by Revenue 2012 and 2013

23.3.5 Geographical Segmentation by Revenue 3

23.3.6 Business Strategy

23.3.7 Key Information

23.3.8 SWOT Analysis

23.4 Sanofi

23.4.1 Key Facts

23.4.2 Business Overview

23.4.3 Business Segmentation by Revenue 2013

23.4.4 Business Segmentation by Revenue 2012 and 2013

23.4.5 Geographical Segmentation by Revenue

23.4.6 Business Strategy

23.4.7 Key Developments

23.4.8 SWOT Analysis

24. Other Reports in this Series